CERS vs QGEN
CERS: Cerus is a developer of blood safety technologies, specifically pathogen reduction systems designed to protect the blood supply from transfusion-transmitted infections. QGEN: QIAGEN supplies essential molecular diagnostic and sample preparation tools that enable laboratories and clinicians to detect, analyze, and validate genetic material and biomarkers.
Side-by-side fundamentals
| Metric | CERS | QGEN | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $2.32 | $41.73 | |
| Market cap as of 2026-08-08 | $468M | $8.7B | |
| P/E as of 2026-08-08 | n/a | 21.68 | |
| PEG as of 2026-08-08 | n/a | 3.48 | |
| Net margin as of 2026-08-08 | -2.7% | +19.2% | QGEN higher |
| Gross margin as of 2026-08-08 | +57.2% | +62.6% | QGEN higher |
| Operating margin as of 2026-08-08 | -0.7% | +20.7% | QGEN higher |
| ROE as of 2026-08-08 | -10.3% | +11.3% | QGEN higher |
| ROA as of 2026-08-08 | -3.1% | +6.6% | QGEN higher |
| Debt / equity as of 2026-08-08 | 0.93 | 0.49 | QGEN lower |
| Revenue growth (YoY) as of 2026-08-08 | +14.6% | +4.8% | CERS higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | -0.8% | CERS higher |
| Dividend yield as of 2026-08-08 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-08-08 | 1.80 | 0.61 | |
| 1-year return as of 2026-08-06 close | +79.8% | -12.1% | CERS higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.